The number of targeted therapies available for the treatment of different cancers increases annually. However, for many of these agents, we do not have effective predictive biomarkers. The result is that patients who might benefit for certain therapies are not receiving them, and patients receive therapies from which they receive no benefit. In many cases, it is likely that an individual drug might be effective in only a small subset of a particular cancer, so that without a validated predictive biomarker, introduction to that cancer is impossible. W propose a novel and generalizable functional predictive biomarker approach, based on measuring death signaling early in the response to targeted therapies. We hypothesize that if we could identify those cancer cells that induce the strongest activation ofthe mitochondrial apoptotic pathway at early time points in response to a drug, we could thus identify those tumors that are most likely to respond in vivo. We are greatly assisted in this approach by our development of a novel tool, BH3 profiling, which can measure a cell's proximity to the threshold of apoptosis. Our approach is to treat cells with drugs, measure at short time points the extent to which apoptotic signaling is forcing cells toward the threshold of apoptosis, a method we call Dynamic BH3 Profiling. As we will show, we are now adept at making such measurements. Moreover, we already have exciting preliminary data that suggests that those cells that are pushed the most are also those that are destined to choose death as a cell fate. We propose to develop Dynamic BH3 profling first in AML cell lines, and then in murine AML primagrafts. Our output will be a set of drugs for which we have validated Dynamic BH3 profiling as a predicitve biomarker in vivo. These drugs might be useful as single agents, or as agents to increase priming to enhance sensitiity to conventional, curative agents. Acute myelogenous leukemia (AML) is an attractive disease in which to test our ideas because of our established expertise, established relationships, and access to clinical samples. Dynamic BH3 profling has the potential to expand the pharmacopeia and personalize therapeutic decision making for the AML patient.
The number of Innovative targeted therapies for cancer is increasing. However, oncologists still do not have the information they need to make sure that individual cancer patients are being matched with the targeted therapies that best meet their needs. In this application we propose a novel approach, dynamic BH3 profling, to personalizing cancer therapy by measuring changes in cancer cells induced by targeted therapies.
|Wan, Liling; Wen, Hong; Li, Yuanyuan et al. (2017) ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543:265-269|
|Weisberg, Ellen L; Puissant, Alexandre; Stone, Richard et al. (2017) Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 8:52026-52044|
|Pallis, Monica; Burrows, Francis; Ryan, Jeremy et al. (2017) Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget 8:16220-16232|
|Tamura, Akihiro; Hirai, Hideyo; Yokota, Asumi et al. (2017) C/EBP? is required for survival of Ly6C- monocytes. Blood 130:1809-1818|
|Toska, Eneda; Osmanbeyoglu, Hatice U; Castel, Pau et al. (2017) PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science 355:1324-1330|
|Shortt, Jake; Ott, Christopher J; Johnstone, Ricky W et al. (2017) A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer 17:160-183|
|Gonzalez, David; Luyten, Annouck; Bartholdy, Boris et al. (2017) ZNF143 is an important regulator of the myeloid transcription factor C/EBP?. J Biol Chem :|
|Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8|
|Valerio, Daria G; Xu, Haiming; Chen, Chun-Wei et al. (2017) Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 77:1753-1762|
|Li, Hubo; Mar, Brenton G; Zhang, Huadi et al. (2017) The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood 129:497-508|
Showing the most recent 10 out of 303 publications